Gan & Lee Pharmaceuticals.
603087
Peringkat dalam Saham
#3011
Gan & Lee Pharmaceuticals is a biopharmaceutical enterprise primarily focused... Gan & Lee Pharmaceuticals is a biopharmaceutical enterprise primarily focused on the discovery, development, manufacturing, and marketing of insulin analogues within the Chinese market. Their diverse product portfolio encompasses injectable therapies such as Basalin (an insulin glargine), Prandilin (an insulin lispro), Prandilin 25 (another insulin lispro variant), Raplin (an insulin aspart), Raplin 30 (an insulin aspart 30 formulation), and Similin 30 (an insulin injection). Beyond diabetes treatments, the company also offers various medical devices. Established in 1998, Gan & Lee Pharmaceuticals maintains its corporate headquarters in Beijing, People's Republic of China. The organization underwent a name change in April 2005, transitioning from its former identity as Beijing Gan & Lee Biotechnology Co., Ltd.
Harga Saham
$10.03
Kapitalisasi Pasar
$5.99B
Perubahan (1 hari)
-3.71%
Perubahan (1 tahun)
2.30%
Negara
CN
Perdagangan Gan & Lee Pharmaceuticals. (603087)
Kategori
Healthcare
Pendapatan untuk Gan & Lee Pharmaceuticals. (603087)
Pendapatan pada Oct 2026 TTM: 0
Menurut laporan keuangan terbaru dari Gan & Lee Pharmaceuticals., pendapatan saat ini (TTM) adalah 0. Pada tahun 2026, perusahaan menghasilkan pendapatan sebesar 0 sama dengan pendapatan pada tahun 2026 yang sebesar 0. Pendapatan adalah jumlah total yang dihasilkan dari penjualan barang atau jasa. Tidak seperti laba, tidak ada pengeluaran yang dikurangkan.
Riwayat pendapatan Gan & Lee Pharmaceuticals. dari 2013 hingga 2026
Pendapatan pada akhir setiap tahun
| Tahun | Pendapatan | Mengubah |
|---|---|---|
| 2025 | $577.49M | 38.41% |
| 2024 | $417.22M | 13.24% |
| 2023 | $368.44M | 48.43% |
| 2022 | $248.23M | -56.32% |
| 2021 | $568.30M | 10.43% |
| 2020 | $514.62M | 23.78% |
| 2019 | $415.76M | 19.79% |
| 2018 | $347.07M | -4.74% |
| 2017 | $364.35M | 42.80% |
| 2016 | $255.15M | 35.83% |
| 2015 | $187.84M | 25.57% |
| 2014 | $149.60M | 31.01% |
| 2013 | $114.19M | 0.00% |
Pendapatan untuk perusahaan serupa atau pesaing
| Perusahaan | Pendapatan | Perbedaan Pendapatan | Negara |
|---|---|---|---|
| $11.58B | - |
US
|
|
| $34.74B | - |
FR
|
|
| - | - |
JP
|
|
| $20.84B | - |
US
|
|
| - | - |
CH
|
